Covered recipient · General Payments record
PERMINDER J S BHATIA
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$21,332.91
314 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $8,750.00 | 5 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,341.83 | 7 |
| Food and Beverage | $5,717.52 | 298 |
| Travel and Lodging | $252.42 | 1 |
| Consulting Fee | $150.00 | 1 |
| Education | $121.14 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 5 of 7; records 201–250 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PERMINDER J S BHATIA
NPI 1013002328 · CMS profile ID 45675
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
FRESNO, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 7; records 201–250 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1013002328?year=2021&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PERMINDER J S BHATIA, NPI 1013002328, CMS profile ID 45675. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013002328?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). PERMINDER J S BHATIA, NPI 1013002328, CMS profile ID 45675. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013002328?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- PERMINDER J S BHATIA, NPI 1013002328, CMS profile ID 45675, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 7; records 201–250 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1013002328?year=2021&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
314 matching records · $21,332.91 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–250 of 314.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| SK Life Science, Inc. | $9.70 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826818981 | CMS |
| Sunovion Pharmaceuticals Inc. | $16.54 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821769577 | CMS |
| Neurelis, Inc. | $21.53 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842860057 | CMS |
| Teva Pharmaceuticals USA, Inc. | $16.47 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839513373 | CMS |
| Teva Pharmaceuticals USA, Inc. | $19.99 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839513375 | CMS |
| CATALYST PHARMACEUTICALS, INC. | $18.53 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 828332659 | CMS |
| LivaNova USA, Inc. | $20.24 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844254869 | CMS |
| Biohaven Pharmaceuticals, Inc. | $22.11 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852428231 | CMS |
| Amneal Pharmaceuticals LLC | $15.85 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829646951 | CMS |
| Mallinckrodt Hospital Products Inc. | $0.64 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845346965 | CMS |
| Mallinckrodt Hospital Products Inc. | $7.37 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845346967 | CMS |
| BOSTON SCIENTIFIC CORPORATION | $89.42 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 777701029 | CMS |
| Biogen, Inc. | $20.69 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827852959 | CMS |
| SK Life Science, Inc. | $23.21 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826818979 | CMS |
| Allergan, Inc. | $23.94 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792708069 | CMS |
| Kyowa Kirin, Inc. | $22.50 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852982321 | CMS |
| Novartis Pharmaceuticals Corporation | $13.00 | 05/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812609533 | CMS |
| Celgene Corporation | $17.71 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783678541 | CMS |
| Alexion Pharmaceuticals, Inc. | $3.13 | 05/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783122259 | CMS |
| Amgen Inc. | $31.58 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825683991 | CMS |
| Eisai Inc. | $15.40 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 817907505 | CMS |
| Novartis Pharmaceuticals Corporation | $16.58 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812609535 | CMS |
| Adamas Pharmaceuticals, Inc. | $21.57 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834395761 | CMS |
| Biohaven Pharmaceuticals, Inc. | $1,125.00 | 04/29/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852428227 | CMS |
| UCB, Inc. | $20.51 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807339913 | CMS |
| Biogen, Inc. | $18.34 | 04/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827852955 | CMS |
| Teva Pharmaceuticals USA, Inc. | $18.71 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839513371 | CMS |
| EMD Serono, Inc. | $14.88 | 04/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849175037 | CMS |
| Novartis Pharmaceuticals Corporation | $19.93 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812609531 | CMS |
| Sunovion Pharmaceuticals Inc. | $18.72 | 04/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821697693 | CMS |
| Kyowa Kirin, Inc. | $17.19 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852982319 | CMS |
| Allergan, Inc. | $6.94 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792708067 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.35 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829861855 | CMS |
| BANNER LIFE SCIENCES, LLC | $900.00 | 04/13/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843736887 | CMS |
| Teva Pharmaceuticals USA, Inc. | $18.87 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839513369 | CMS |
| Amneal Pharmaceuticals LLC | $19.87 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829646945 | CMS |
| EMD Serono, Inc. | $91.82 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849172207 | CMS |
| Lilly USA, LLC | $18.14 | 04/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818686687 | CMS |
| SK Life Science, Inc. | $900.00 | 04/08/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826819021 | CMS |
| Acorda Therapeutics, Inc | $12.41 | 04/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792552033 | CMS |
| Alexion Pharmaceuticals, Inc. | $25.39 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783122255 | CMS |
| Novartis Pharmaceuticals Corporation | $14.46 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812609529 | CMS |
| LivaNova USA, Inc. | $17.27 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844254851 | CMS |
| Mallinckrodt Hospital Products Inc. | $19.36 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845346963 | CMS |
| UCB, Inc. | $21.67 | 03/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807338023 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.09 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830105211 | CMS |
| Biogen, Inc. | $13.07 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827852953 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.71 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783438649 | CMS |
| EMD Serono, Inc. | $8.85 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849169185 | CMS |
| SK Life Science, Inc. | $3,250.00 | 03/22/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826819009 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,405.53 | 6 |
| PY2025 | Principal investigator | $1,597,612.15 | 218 |
| PY2024 | Recipient | $1,621.97 | 3 |
| PY2024 | Principal investigator | $1,125,524.72 | 121 |
| PY2023 | Recipient | $465.64 | 2 |
| PY2023 | Principal investigator | $1,137,330.81 | 86 |
| PY2022 | Recipient | $3,881.00 | 3 |
| PY2022 | Principal investigator | $1,670,191.56 | 73 |
| PY2021 | Recipient | $444.81 | 1 |
| PY2021 | Principal investigator | $885,391.87 | 74 |
| PY2020 | Principal investigator | $653,742.50 | 69 |
| PY2019 | Principal investigator | $906,341.06 | 121 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
224 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,242.56 | 12/31/2025 | Covered Recipient Teaching Hospital EMORY UNIVERSITY HOSPITAL | A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202411598 |
| Principal investigator 1 | ABBVIE INC. | $1,854.00 | 12/31/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER | A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine | No dispute reported | 06/30/2026 | 1202533953 |
| Principal investigator 1 | ABBVIE INC. | $962.76 | 12/31/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER | A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age | No dispute reported | 06/30/2026 | 1202533955 |
| Principal investigator 1 | ABBVIE INC. | $582.00 | 12/31/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER | A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine | No dispute reported | 06/30/2026 | 1202533957 |
| Principal investigator 1 | ABBVIE INC. | $1,440.00 | 12/31/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202533959 |
| Principal investigator 1 | ABBVIE INC. | $828.36 | 12/31/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER | An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson s Disease | No dispute reported | 06/30/2026 | 1202533961 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension | No dispute reported | 06/30/2026 | 1202535381 |
| Principal investigator 1 | SK Life Science, Inc. | $850.00 | 12/24/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER INC. | YKP3089C025 | No dispute reported | 06/30/2026 | 1252274877 |
| Principal investigator 1 | SK Life Science, Inc. | $1,000.00 | 12/24/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER INC. | YKP3089C025 | No dispute reported | 06/30/2026 | 1252274879 |
| Principal investigator 1 | Ipsen Innovation | $7,500.00 | 12/19/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287682 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $241.00 | 12/17/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045208 |
| Principal investigator 1 | ABBVIE INC. | $1,224.60 | 12/04/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202529024 |
| Principal investigator 1 | ABBVIE INC. | $1,837.35 | 12/04/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202529026 |
| Principal investigator 1 | H. Lundbeck A S | $2,380.00 | 12/01/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251777903 |
| Principal investigator 1 | H. Lundbeck A S | $2,006.00 | 12/01/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251777907 |
| Principal investigator 1 | H. Lundbeck A S | $1,902.00 | 12/01/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251777912 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 12/01/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287684 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 12/01/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287686 |
| Principal investigator 1 | Ipsen Pharma SAS | $750.00 | 11/24/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184303397 |
| Principal investigator 1 | Ipsen Innovation | $1,721.33 | 11/19/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287680 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $638.00 | 11/19/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045202 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $241.00 | 11/19/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045204 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $838.00 | 11/19/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045206 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $241.00 | 11/19/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045358 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $838.00 | 11/19/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045360 |
| Principal investigator 1 | ABBVIE INC. | $1,820.00 | 11/13/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202524099 |
| Principal investigator 1 | ABBVIE INC. | $693.00 | 11/13/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202524101 |
| Principal investigator 1 | ABBVIE INC. | $612.30 | 11/05/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202522053 |
| Principal investigator 1 | Ipsen Innovation | $1,757.21 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287638 |
| Principal investigator 1 | Ipsen Innovation | $1,757.21 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287640 |
| Principal investigator 1 | Ipsen Innovation | $2,060.21 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287642 |
| Principal investigator 1 | Ipsen Innovation | $2,918.50 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287644 |
| Principal investigator 1 | Ipsen Innovation | $2,918.50 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287646 |
| Principal investigator 1 | Ipsen Innovation | $2,918.50 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287648 |
| Principal investigator 1 | Ipsen Innovation | $2,918.50 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287650 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287652 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287654 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287656 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287658 |
| Principal investigator 1 | Ipsen Innovation | $1,565.53 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287660 |
| Principal investigator 1 | Ipsen Innovation | $1,687.96 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287662 |
| Principal investigator 1 | Ipsen Innovation | $1,757.21 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287664 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287666 |
| Principal investigator 1 | Ipsen Innovation | $2,918.50 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287668 |
| Principal investigator 1 | Ipsen Innovation | $2,084.33 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287670 |
| Principal investigator 1 | Ipsen Innovation | $2,439.64 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287672 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287674 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287676 |
| Principal investigator 1 | Ipsen Innovation | $2,918.50 | 10/22/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287678 |
| Principal investigator 1 | H. Lundbeck A S | $327.00 | 10/15/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251775693 |
| Principal investigator 1 | SK Life Science, Inc. | $1,678.25 | 10/15/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER INC. | YKP3089C049 | No dispute reported | 06/30/2026 | 1252274845 |
| Principal investigator 1 | ABBVIE INC. | $15,370.31 | 10/14/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202516739 |
| Principal investigator 1 | ABBVIE INC. | $3,105.70 | 10/09/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202515399 |
| Principal investigator 1 | ABBVIE INC. | $813.70 | 10/09/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202516171 |
| Principal investigator 1 | ABBVIE INC. | $284.85 | 10/09/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202516173 |
| Principal investigator 1 | ABBVIE INC. | $236.93 | 10/09/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202516467 |
| Principal investigator 1 | H. Lundbeck A S | $7,793.00 | 10/08/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251775490 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 09/29/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287636 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $632.00 | 09/24/2025 | Non-covered Recipient Entity THE CENTER FOR CLINICAL RESEARCH LLC | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067693 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $2,147.60 | 09/24/2025 | Non-covered Recipient Entity THE CENTER FOR CLINICAL RESEARCH LLC | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067695 |
| Principal investigator 1 | Roche Products Limited | $91.80 | 09/24/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211628093 |
| Principal investigator 1 | H. Lundbeck A S | $2,380.00 | 09/10/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251774444 |
| Principal investigator 1 | H. Lundbeck A S | $1,902.00 | 09/10/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251774449 |
| Principal investigator 1 | H. Lundbeck A S | $327.00 | 09/10/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251774454 |
| Principal investigator 1 | ABBVIE INC. | $1,837.35 | 09/04/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202508728 |
| Principal investigator 1 | Ipsen Innovation | $126.00 | 08/19/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287634 |
| Principal investigator 1 | ABBVIE INC. | $3,939.04 | 08/13/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202504471 |
| Principal investigator 1 | ABBVIE INC. | $2,501.55 | 08/05/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202501800 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 07/30/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202500472 |
| Principal investigator 1 | ABBVIE INC. | $560.00 | 07/30/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202500474 |
| Principal investigator 1 | ABBVIE INC. | $75.00 | 07/30/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202500476 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287600 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287602 |
| Principal investigator 1 | Ipsen Innovation | $1,757.21 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287604 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287606 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287608 |
| Principal investigator 1 | Ipsen Innovation | $1,910.93 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287610 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287612 |
| Principal investigator 1 | Ipsen Innovation | $1,687.96 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287614 |
| Principal investigator 1 | Ipsen Innovation | $2,060.21 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287616 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287618 |
| Principal investigator 1 | Ipsen Innovation | $1,910.93 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287620 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287622 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287624 |
| Principal investigator 1 | Ipsen Innovation | $1,687.96 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287626 |
| Principal investigator 1 | Ipsen Innovation | $2,060.21 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287628 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287630 |
| Principal investigator 1 | Ipsen Innovation | $1,910.93 | 07/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287632 |
| Principal investigator 1 | ABBVIE INC. | $75.00 | 07/18/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202498930 |
| Principal investigator 1 | SK Life Science, Inc. | $2,387.00 | 07/16/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER INC. | YKP3089C049 | No dispute reported | 06/30/2026 | 1252274835 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,000.00 | 07/14/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045200 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $241.00 | 07/11/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045198 |
| Principal investigator 1 | ABBVIE INC. | $791.10 | 07/02/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202495047 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 07/02/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 1202495855 |
| Principal investigator 1 | ABBVIE INC. | $1,888.90 | 07/02/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 1202495857 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,699.65 | 06/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184303387 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,699.65 | 06/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184303389 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,699.65 | 06/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184303391 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,699.65 | 06/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184303393 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,699.65 | 06/30/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184303395 |
| Principal investigator 1 | ABBVIE INC. | $13,664.00 | 06/26/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202493169 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 06/26/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 1202493183 |
| Principal investigator 1 | ABBVIE INC. | $163.80 | 06/26/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202493185 |
| Principal investigator 1 | ABBVIE INC. | $2,684.00 | 06/26/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202493187 |
| Principal investigator 1 | ABBVIE INC. | $1,042.60 | 06/26/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202493189 |
| Principal investigator 1 | ABBVIE INC. | $473.20 | 06/26/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202493191 |
| Principal investigator 1 | H. Lundbeck A S | $2,000.00 | 06/26/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Cognitive interview study to evaluate phase 2 trial anchors in patients with Parkinsons Disease | No dispute reported | 06/30/2026 | 1251771661 |
| Principal investigator 1 | H. Lundbeck A S | $3,300.00 | 06/26/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Cognitive interview study to evaluate phase 2 trial anchors in patients with Parkinsons Disease | No dispute reported | 06/30/2026 | 1251771665 |
| Principal investigator 1 | ABBVIE INC. | $731.25 | 06/24/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202492791 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 06/24/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202492793 |
| Principal investigator 1 | ABBVIE INC. | $843.75 | 06/24/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202492795 |
| Principal investigator 1 | Roche Products Limited | $306.00 | 06/24/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211628084 |
| Principal investigator 1 | Roche Products Limited | $306.00 | 06/24/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211628089 |
| Principal investigator 1 | ABBVIE INC. | $2,476.18 | 06/19/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202492445 |
| Principal investigator 1 | ABBVIE INC. | $594.00 | 06/05/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202490587 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 06/05/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202490591 |
| Principal investigator 1 | ABBVIE INC. | $2,224.20 | 06/03/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202488051 |
| Principal investigator 1 | ABBVIE INC. | $43,420.00 | 05/29/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202487089 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $208.00 | 05/22/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies | No dispute reported | 06/30/2026 | 1185552095 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,000.00 | 05/19/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184303381 |
| Principal investigator 1 | Ipsen Pharma SAS | $750.00 | 05/19/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184303383 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,500.00 | 05/19/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184303385 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $638.00 | 05/14/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045194 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $241.00 | 05/14/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045196 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $638.00 | 05/14/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045346 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $638.00 | 05/14/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045348 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $638.00 | 05/14/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045350 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $638.00 | 05/14/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045352 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $638.00 | 05/14/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045354 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $638.00 | 05/14/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045356 |
| Principal investigator 1 | Eli Lilly and Company | $14,230.00 | 05/13/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | No dispute reported | 06/30/2026 | 1187887066 |
| Principal investigator 1 | ABBVIE INC. | $3,817.95 | 05/07/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202483735 |
| Principal investigator 1 | ABBVIE INC. | $12,802.00 | 05/07/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202484029 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $3,170.00 | 05/07/2025 | Non-covered Recipient Entity THE CENTER FOR CLINICAL RESEARCH LLC | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248066377 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $1,500.00 | 05/07/2025 | Non-covered Recipient Entity THE CENTER FOR CLINICAL RESEARCH LLC | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248066379 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $7,148.00 | 05/07/2025 | Non-covered Recipient Entity THE CENTER FOR CLINICAL RESEARCH LLC | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248066381 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $1,200.00 | 05/07/2025 | Non-covered Recipient Entity THE CENTER FOR CLINICAL RESEARCH LLC | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248066383 |
| Principal investigator 1 | ABBVIE INC. | $1,960.20 | 05/06/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202482245 |
| Principal investigator 1 | ABBVIE INC. | $1,977.75 | 05/06/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202482247 |
| Principal investigator 1 | Ipsen Innovation | $2,984.04 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287556 |
| Principal investigator 1 | Ipsen Innovation | $2,439.64 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287558 |
| Principal investigator 1 | Ipsen Innovation | $1,687.96 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287560 |
| Principal investigator 1 | Ipsen Innovation | $1,910.93 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287562 |
| Principal investigator 1 | Ipsen Innovation | $1,565.53 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287564 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287566 |
| Principal investigator 1 | Ipsen Innovation | $2,559.60 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287568 |
| Principal investigator 1 | Ipsen Innovation | $1,565.53 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287570 |
| Principal investigator 1 | Ipsen Innovation | $2,439.64 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287572 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287574 |
| Principal investigator 1 | Ipsen Innovation | $2,060.21 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287576 |
| Principal investigator 1 | Ipsen Innovation | $1,687.96 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287578 |
| Principal investigator 1 | Ipsen Innovation | $1,565.53 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287580 |
| Principal investigator 1 | Ipsen Innovation | $2,984.04 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287582 |
| Principal investigator 1 | Ipsen Innovation | $2,060.21 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287584 |
| Principal investigator 1 | Ipsen Innovation | $2,439.64 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287586 |
| Principal investigator 1 | Ipsen Innovation | $2,984.04 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287588 |
| Principal investigator 1 | Ipsen Innovation | $2,984.04 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287590 |
| Principal investigator 1 | Ipsen Innovation | $1,565.53 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287592 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287594 |
| Principal investigator 1 | Ipsen Innovation | $689.20 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287596 |
| Principal investigator 1 | Ipsen Innovation | $2,984.04 | 04/28/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184287598 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 04/24/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202479409 |
| Principal investigator 1 | SK Life Science, Inc. | $1,491.85 | 04/23/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER INC. | YKP3089C049 | No dispute reported | 06/30/2026 | 1252274801 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $40,794.72 | 04/14/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER | A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214124850 |
| Principal investigator 1 | ABBVIE INC. | $8,564.50 | 04/10/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) | No dispute reported | 06/30/2026 | 1202476103 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $2,141.30 | 04/04/2025 | Non-covered Recipient Entity Neuro Pain Medical Center Inc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248068423 |
| Principal investigator 1 | ABBVIE INC. | $2,883.40 | 04/03/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202473635 |
| Principal investigator 1 | ABBVIE INC. | $1,221.15 | 04/03/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202473827 |
| Principal investigator 1 | ABBVIE INC. | $2,188.55 | 04/03/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202473831 |
| Principal investigator 1 | ABBVIE INC. | $2,612.25 | 04/03/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202473833 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,699.65 | 04/01/2025 | Non-covered Recipient Entity Dr Bhatias Neuropain Medical Center | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184303379 |
| Principal investigator 1 | Eli Lilly and Company | $256,357.00 | 03/19/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187884890 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $638.00 | 03/14/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045192 |
| Principal investigator 1 | ABBVIE INC. | $3,211.26 | 03/13/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202463814 |
| Principal investigator 1 | ABBVIE INC. | $12,052.00 | 03/07/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | M23-712 - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202461275 |
| Principal investigator 1 | ABBVIE INC. | $6,325.65 | 03/07/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202461279 |
| Principal investigator 1 | ABBVIE INC. | $1,750.32 | 03/06/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202458135 |
| Principal investigator 1 | ABBVIE INC. | $17,917.93 | 03/06/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202459047 |
| Principal investigator 1 | H. Lundbeck A S | $370.36 | 03/05/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251768236 |
| Principal investigator 1 | H. Lundbeck A S | $238.89 | 03/05/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251768240 |
| Principal investigator 1 | H. Lundbeck A S | $123.64 | 03/05/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251768244 |
| Principal investigator 1 | H. Lundbeck A S | $26.05 | 03/05/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251768248 |
| Principal investigator 1 | H. Lundbeck A S | $25.00 | 03/05/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251768252 |
| Principal investigator 1 | H. Lundbeck A S | $126.60 | 03/05/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251768256 |
| Principal investigator 1 | H. Lundbeck A S | $477.01 | 02/27/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251767940 |
| Principal investigator 1 | Eli Lilly and Company | $2,049.50 | 02/25/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187887020 |
| Principal investigator 1 | ABBVIE INC. | $150.00 | 02/06/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202447521 |
| Principal investigator 1 | ABBVIE INC. | $1,273.78 | 02/05/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202444443 |
| Principal investigator 1 | ABBVIE INC. | $573.30 | 02/05/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER | M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202446496 |
| Principal investigator 1 | ABBVIE INC. | $3,291.30 | 02/05/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202446499 |
| Principal investigator 1 | UCB SA | $27,104.95 | 02/05/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease | No dispute reported | 06/30/2026 | 1246657562 |
| Principal investigator 1 | Eli Lilly and Company | $615.74 | 01/31/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187884892 |
| Principal investigator 1 | Eli Lilly and Company | $570.00 | 01/31/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY | No dispute reported | 06/30/2026 | 1187885654 |
| Principal investigator 1 | Eli Lilly and Company | $2,720.35 | 01/31/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187886984 |
| Principal investigator 1 | Eli Lilly and Company | $306.56 | 01/31/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187887064 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $11,896.85 | 01/31/2025 | Non-covered Recipient Entity Neuro Pain Medical Center Inc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248066259 |
| Principal investigator 1 | Eli Lilly and Company | $9,933.14 | 01/27/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187886204 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $638.00 | 01/22/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045188 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $241.00 | 01/22/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045190 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $638.00 | 01/22/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045342 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $638.00 | 01/22/2025 | Non-covered Recipient Entity Neuropain Medical Center Inc | TV50717-CNS-40223 | No dispute reported | 06/30/2026 | 1244045344 |
| Principal investigator 1 | Eli Lilly and Company | $218,226.00 | 01/21/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187884416 |
| Principal investigator 1 | Eli Lilly and Company | $56,716.00 | 01/21/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187885290 |
| Principal investigator 1 | Eli Lilly and Company | $132,434.00 | 01/21/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187887016 |
| Recipient | ACADIA Pharmaceuticals Inc | $319.51 | 01/17/2025 | Covered Recipient Physician | ACP-204 | No dispute reported | 06/30/2026 | 1245932619 |
| Recipient | ACADIA Pharmaceuticals Inc | $463.96 | 01/17/2025 | Covered Recipient Physician | ACP-204 | No dispute reported | 06/30/2026 | 1245932621 |
| Recipient | ACADIA Pharmaceuticals Inc | $230.25 | 01/17/2025 | Covered Recipient Physician | ACP-204 | No dispute reported | 06/30/2026 | 1245932623 |
| Recipient | ACADIA Pharmaceuticals Inc | $96.81 | 01/17/2025 | Covered Recipient Physician | ACP-204 | No dispute reported | 06/30/2026 | 1245932625 |
| Recipient | ACADIA Pharmaceuticals Inc | $125.00 | 01/17/2025 | Covered Recipient Physician | ACP-204 | No dispute reported | 06/30/2026 | 1245932627 |
| Recipient | ACADIA Pharmaceuticals Inc | $170.00 | 01/17/2025 | Covered Recipient Physician | ACP-204 | No dispute reported | 06/30/2026 | 1245932629 |
| Principal investigator 1 | UCB SA | $18,220.00 | 01/17/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE | No dispute reported | 06/30/2026 | 1246658720 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $190.00 | 01/14/2025 | Non-covered Recipient Entity Neuro Pain Medical Center Inc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248066257 |
| Principal investigator 1 | Eli Lilly and Company | $5.79 | 01/09/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187886202 |
| Principal investigator 1 | Roche Products Limited | $306.00 | 01/09/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211628063 |
| Principal investigator 1 | Roche Products Limited | $306.00 | 01/09/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211628069 |
| Principal investigator 1 | Roche Products Limited | $306.00 | 01/09/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211628073 |
| Principal investigator 1 | Roche Products Limited | $306.00 | 01/09/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211628078 |
| Principal investigator 1 | UCB SA | $12,444.90 | 01/09/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE (AD), FOLLOWED BY AN OPEN-LABEL EXTENSION PERIOD | No dispute reported | 06/30/2026 | 1246659398 |
| Principal investigator 1 | UCB SA | $57,973.45 | 01/08/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY Parkinsons DISEASE | No dispute reported | 06/30/2026 | 1246657333 |
| Principal investigator 1 | Eli Lilly and Company | $94,433.00 | 01/07/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187886564 |
| Principal investigator 1 | Eli Lilly and Company | $114,224.00 | 01/07/2025 | Non-covered Recipient Entity NEURO PAIN MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY | No dispute reported | 06/30/2026 | 1187887018 |
| Principal investigator 1 | ABBVIE INC. | $4,125.08 | 01/02/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202434083 |
| Principal investigator 1 | ABBVIE INC. | $4,433.40 | 01/02/2025 | Non-covered Recipient Entity NEURO-PAIN MEDICAL CENTER INC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202436304 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $116,355.16 | 01/01/2025 | Non-covered Recipient Entity NEUROPAIN MEDICAL CENTER | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214123704 |